Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Key Risk Factors and Clinical Insights
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease (NAFLD), is the most common chronic liver condition worldwide. It affects approximately 32% of the U.S. Adult population and is strongly linked to metabolic syndrome components such as obesity, insulin resistance, dyslipidemia, and hypertension.
Recent research utilizing data from the All of Us Research Program has provided deeper insight into the metabolic risk factors and clinical presentations of MASLD across diverse populations. This large-scale, longitudinal study confirms that individuals with multiple metabolic risk factors—particularly central obesity, elevated fasting glucose, high triglycerides, low HDL cholesterol, and hypertension—are at significantly increased risk for developing MASLD.
The condition often progresses silently, with many patients remaining asymptomatic until advanced liver damage occurs. In some cases, MASLD can advance to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, or hepatocellular carcinoma. Early detection through noninvasive screening methods—including liver ultrasound, fibrosis scores (such as FIB-4), and controlled attenuation parameter (CAP)—is critical for timely intervention.
Lifestyle modification remains the cornerstone of MASLD management. Evidence-based recommendations include achieving 7–10% weight loss through calorie-restricted diets and increased physical activity, adopting a Mediterranean-style eating pattern, and avoiding alcohol and hepatotoxic substances. For patients with comorbid type 2 diabetes, certain glucose-lowering medications—such as glucagon-like peptide-1 (GLP-1) receptor agonists—have shown promise in improving liver histology.
Public health efforts must prioritize awareness, early screening, and equitable access to care, particularly in underserved communities where MASLD prevalence is rising rapidly due to socioeconomic disparities in nutrition, physical activity, and healthcare access.
Key Takeaways
- MASLD affects about one in three U.S. Adults and is the leading cause of chronic liver disease.
- Core metabolic risk factors include obesity, insulin resistance, dyslipidemia, and hypertension.
- The condition is often asymptomatic in early stages, underscoring the importance of proactive screening.
- Lifestyle intervention—particularly weight loss and dietary improvement—is the primary treatment strategy.
- Emerging pharmacotherapies, including GLP-1 receptor agonists, reveal potential for patients with MASLD and type 2 diabetes.
Frequently Asked Questions
- What is MASLD, and how is it different from NAFLD?
- MASLD (metabolic dysfunction-associated steatotic liver disease) is the updated term for what was formerly called NAFLD (nonalcoholic fatty liver disease). The name change reflects a stronger emphasis on the underlying metabolic dysfunction driving liver fat accumulation, rather than simply excluding alcohol as a cause.
- Can MASLD be reversed?
- In its early stages, MASLD can often be reversed or significantly improved through sustained lifestyle changes, including weight loss, regular exercise, and dietary modifications. However, advanced fibrosis or cirrhosis may not be fully reversible.
- Who should be screened for MASLD?
- Individuals with obesity, type 2 diabetes, metabolic syndrome, or elevated liver enzymes should discuss screening with their healthcare provider. Screening may include liver ultrasound, blood tests, and noninvasive fibrosis assessments.
- Are there medications approved specifically for MASLD?
- As of now, no medication is FDA-approved exclusively for MASLD. However, drugs used to treat comorbid conditions—such as GLP-1 receptor agonists for diabetes and obesity, or vitamin E in select cases—may benefit liver health under medical supervision.